A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses

ανά Boyd, Zachary S., Raja, Rajiv, Johnson, Stephanie, Eberhard, David A., Lackner, Mark R.
Έκδοση 2009

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

ανά Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony
Τόπος έκδοσης J Hepatol (2020)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

ανά Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Τόπος έκδοσης J Immunother Cancer (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

ανά Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Τόπος έκδοσης J Immunother Cancer (2015)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

ανά Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary
Τόπος έκδοσης Appl Immunohistochem Mol Morphol (2019)

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

ανά Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Τόπος έκδοσης Lancet (2016)